<DOC>
	<DOCNO>NCT02864251</DOCNO>
	<brief_summary>The purpose study determine whether Nivolumab+ chemotherapy Nivolumab+Ipilimumab effective treatment patient EGFR mutation , T790M negative NSCLC fail first line ( 1L ) EGFR TKI therapy</brief_summary>
	<brief_title>A Study Nivolumab + Chemotherapy Nivolumab + Ipilimumab Versus Chemotherapy Patients With EGFR Mutation , T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Confirmed stage IV recurrent EGFR Mutation ( MT ) + NSCLC disease progression 1 prior EGFR TKI therapy No evidence exon 20 T790M mutation progression prior EGFR tyrosine kinase inhibitor ( TKI ) therapy . Measurable disease accord Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) Available tumor sample Programmed deathligand 1 ( PDL1 ) immunohistochemical ( IHC ) exon 20 T790M test Subjects symptomatic central nervous system ( CNS ) metastases Subjects carcinomatous meningitis Subjects active , know suspected autoimmune disease exclude Subjects know SCLC transformation Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>